NEW YORK, Jan. 17 /PRNewswire/ -- Aerocrine Inc., wholly owned subsidiary of Aerocrine AB, Sweden, has announced their acquisition of a long-term lease in New Providence, New Jersey where they have relocated their technical services and logistics complex for the United States. Aerocrine was assisted in the move by local industrial property locators Staubach, and property managers, David Cronheim Company.
"This facility will give us the space we need to better service our rapidly growing customers base," said Trevor Bourke, President of Aerocrine Inc. "Asthma is an increasing health care problem today affecting 30 million Americans. NIOX(R), Aerocrine´s lead product is the first device available for routine clinical monitoring of inflammation in the airways of asthma patients. By measuring airway inflammation, the main pathogenic factor in asthma, NIOX helps doctors monitor and treat asthma patients more accurately in a range of clinical settings."
NIOX is an easy to use, non-invasive system for a physician to rapidly and accurately establish the inflammatory condition of the lung, allowing them to assess their patient, and importantly the effect of the therapy, on the airways and the disease.
Aerocrine is dedicated to improving the management and care of patients through measurement of airborne markers, primarily nitric oxide (NO) as an effective and reliable method for the diagnosis and ongoing control of diseases.
About Aerocrine
Aerocrine Inc. is a wholly owned subsidiary of Aerocrine AB a medical technology corporation holding an extensive patent portfolio, dedicated to improved asthma management. Using exhaled Nitric Oxide, the response to asthma therapy is monitored non-invasively with NIOX(R), resulting in healthier patients. Aerocrine is located in Sweden with subsidiaries in the US, UK and Germany.
Aerocrine Inc.CONTACT: Trevor T. Bourke of Aerocrine, Inc., +1-212-810-2480, orTrevor.bourke@aerocrine.net
